By Galen Care Partners on Wednesday, 03 January 2018
Category: Galen Care Partners News

Fatigue Tied With Sorafenib, Sunitinib Use in Renal Cell Carcinoma

Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.
Original link
Leave Comments